Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALT

ALT - Altimmune Inc Stock Price, Fair Value and News

$5.11-1.07 (-17.31%)
Market Closed

15/100

ALT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

ALT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.4

Target 3M

$4.95

Target 6M

$4.68

ALT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALT Price Action

Last 7 days

10.6%

Last 30 days

38.9%

Last 90 days

25.6%

Trailing 12 Months

-26.3%

ALT RSI Chart

ALT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALT Valuation

Market Cap

532.7M

Price/Earnings (Trailing)

-6.35

Price/Sales (Trailing)

26.6K

EV/EBITDA

-5.81

Price/Free Cashflow

-6.19

ALT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.4

Target 3M

$4.95

Target 6M

$4.68

ALT Fundamentals

ALT Revenue

Revenue (TTM)

20.0K

ALT Earnings

Earnings (TTM)

-83.9M

Earnings Growth (Yr)

16.77%

Earnings Growth (Qtr)

14.14%

ALT Profitability

EBT Margin

-421305.00%

Return on Equity

-45.21%

Return on Assets

-38.41%

Free Cashflow Yield

-16.16%

ALT Investor Care

Shares Dilution (1Y)

46.58%

Diluted EPS (TTM)

-1.07

ALT Alerts

  • 3 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202520.0K20.0K20.0K0
2024324.5K223.0K121.5K20.0K
2023911.6K37.0K391.0K426.0K
20223.5M2.7M1.8M0
20216.8M6.2M3.4M4.4M
20205.1M4.2M6.4M8.2M
201910.6M9.8M7.8M5.8M
201813.1M12.5M10.6M10.3M
20173.1M5.4M9.0M10.7M
20164.6M4.2M3.9M3.8M
201513.5M11.0M11.2M10.6M
201415.2M14.5M12.0M10.2M
201325.5M23.5M20.3M17.9M
201224.1M24.0M25.4M25.2M
201121.8M22.6M23.4M24.3M
201000021.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Altimmune Inc

ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEhttps://altimmune.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES52

Altimmune Inc Frequently Asked Questions

ALT is the stock ticker symbol of Altimmune Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Altimmune Inc is 532.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALT's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALT is over valued or under valued. Whether Altimmune Inc is cheap or expensive depends on the assumptions which impact Altimmune Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALT.

As of Wed Jan 28 2026, ALT's PE ratio (Price to Earnings) is -6.35 and Price to Sales (PS) ratio is 26.64 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALT PE ratio will change depending on the future growth rate expectations of investors.